Results
|
|
5681.
|
|
|
|
5682.
|
|
|
|
5683.
|
|
|
|
5684.
|
|
|
|
5685.
|
|
|
|
5686.
|
|
|
|
5687.
|
|
|
|
5688.
|
|
|
|
5689.
|
|
|
|
5690.
|
|
|
|
5691.
|
|
|
|
5692.
|
|
|
|
5693.
|
|
|
|
5694.
|
|
|
|
5695.
|
|
|
|
5696.
|
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. [electronic resource] by
- Wilson, Wyndham H
- O'Connor, Owen A
- Czuczman, Myron S
- LaCasce, Ann S
- Gerecitano, John F
- Leonard, John P
- Tulpule, Anil
- Dunleavy, Kieron
- Xiong, Hao
- Chiu, Yi-Lin
- Cui, Yue
- Busman, Todd
- Elmore, Steven W
- Rosenberg, Saul H
- Krivoshik, Andrew P
- Enschede, Sari H
- Humerickhouse, Rod A
Producer: 20110112
In:
The Lancet. Oncology vol. 11
Availability: No items available.
|
|
|
5697.
|
|
|
|
5698.
|
|
|
|
5699.
|
|
|
|
5700.
|
|